NTRB · NutriBand Inc.
$5.81
-0.19 (-3.17%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Sep 4, 2026
The latest filing states the doubt was alleviated.
“Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment”View the 10-Q filed Sep 4, 2026
Market Cap
$72.93M
Shares
12.16M
Volume · Oct 20
3652
Avg daily vol (3M)
65.9K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.00
Open$6.23
Day$5.65–6.30
52W close$2.81–8.99
Avg vol 30d111K
Short int153K · 1.3% float · 1.0d
Short vol36%
DataOct 2021–Oct 2026
Filing10-Q · Sep 4
Up next
filed Sep 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.62M
Trailing 12 months
Net income (TTM)
−$6.96M
Trailing 12 months
Revenue growth YoY
-29.7%
Year over year
Operating margin
-435.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$3.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.4%
Year over year · more shares
Price change (1Y)
-19.8%
Trailing year
Short interest
1.3%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+40%
above
Price vs 50-day avg
+2%
above
RSI (14)
45
neutral
MACD trend
Negative
52-week position
52%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
+60%
trailing
YTD return
+32%
this year
Relative strength
+52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
1 of 18 funds reported for Sep 30 · net +90 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.26% of float · ▼ -13.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
Gross margin
28%
contracting
EPS growth
−161%
Y/Y
Free cash flow
$-5.1M
Balance sheet
$4.4M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
12.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+40%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
52%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
1 of 18 funds reported for Sep 30 · net +90 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.26% of float · ▼ -13.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $6 · 52%
Range high $9
vs 200-day avg +40%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Customer A concentration | 25% | the three months ended April 30, 2026 filing | — |
| Customer B concentration | 20% | the three months ended April 30, 2026 filing | — |
| Customer C concentration | 14% | the three months ended April 30, 2026 filing | — |
| Customer D concentration | 10% | the three months ended April 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTRB
this stock
NutriBand Inc.
|
$72.93M | +32.2% | -4.8% | — | 1.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTRB | +2.6% | -22.8% | +59.6% | -20.2% | +32.2% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +4.1% | -21.9% | +51.9% | -20.7% | +19.8% |